SUBSCRIBE
SUBSCRIBE
Tyler Patchen

Tyler Patchen

Freelance Writer

Tyler is a journalist with over six years of experience in the world of business journalism. He started his career with the Birmingham Business Journal in Birmingham, Alabama writing about health care, technology, sports business and education. He previously worked as a reporter for Endpoints News and for BioSpace, covering biopharma business and manufacturing. Tyler currently lives in Birmingham, Alabama and holds interests in reading, golf and is also a passionate sports fan. You can reach him at tpatchen94@gmail.com.

Pictured: Illustration of a damaged liver/iStock,
Drug Development
89bio Unveils Bullish Long-Term Data for NASH Candidate
Pegozafermin showed statistically significant improvements in treating patients with nonalcoholic steatohepatitis, notching a win in the race to get the first treatment to market for the condition.
November 27, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Illustration of lungs with syringes/Nico
Drug Development
Regeneron and Sanofi Find Further Positive Results for Dupixent in COPD
New data show the biologic significantly reduced exacerbations in chronic obstructive pulmonary disease, confirming positive results from an earlier trial.
November 27, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: AstraZeneca signage at its office in Sweden
FDA
AstraZeneca’s AKT Inhibitor Wins FDA Approval for Combo Breast Cancer Treatment
The company’s Truqap, in combination with its endocrine therapy Faslodex, has been approved by the regulator for adult patients with advanced HR-positive breast cancer with specific biomarker alterations.
November 17, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Bristol Myers Squibb office in California
FDA
BMS Drug Augtyro Gets FDA Approval to Treat ROS1-Positive NSCLC
After Bristol Myers Squibb picked up Augtyro as part of its $4.1 billion takeover of Turning Point Therapeutics last year, the ROS1-positive non-small cell lung cancer drug reached the regulatory finish line on Wednesday.
November 16, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Bayer's office in New Jersey
Policy
Bayer’s Lymphoma Treatment Aliqopa to be Pulled from US Market
After a Phase III trial did not meet its primary endpoint, Bayer will voluntarily withdraw Aliqopa (copanlisib) from the U.S. market following discussions with the FDA.
November 15, 2023
 · 
2 min read
 · 
Tyler Patchen
Neurosurgeon analyzes an MRI, iStock, gorodenkoff
Business
Jazz Inks $770M Deal with GSK Spinout Autifony, Nabs Two Neuro Assets
Under the potential $770.5 million deal announced Tuesday, Autifony Therapeutics is licensing to Jazz Pharmaceuticals two ion channel targets associated with neurological disorders.
November 14, 2023
 · 
2 min read
 · 
Tyler Patchen
External view of Novartis' office in Canada
Novartis Enters into Deal with Legend Biotech for $100 Million Upfront
After success with J&J, Legend strikes another license agreement, this one with Swiss pharma Novartis around CAR-T therapies.
November 13, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Downward arrow in graph showing stock price dropping
Drug Development
Aclaris’ Stock Crashes after Lead Asset Fails Mid-Stage Trial
Pennsylvania-based Aclaris Therapeutics will stop development of zunsemetinib after it failed to meet the primary endpoint in a Phase II study for rheumatoid arthritis.
November 13, 2023
 · 
1 min read
 · 
Tyler Patchen
Pictured: Upward view of skyscrapers/iStock, alice
Business
Lilly, UCB-Backed ViaNautis Scores $25M for Genetic Nanomedicines
The UK-based nanomedicine biotech, previously known as SomaServe, has closed its Series A with some significant biopharma names attached.
November 13, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Illustration showing a downward graph tr
Drug Development
Atara Biotherapeutics’ Stock Plunges Following Phase II MS Trial Failure
The allogeneic T-cell immunotherapy company is now approaching penny stock territory after its multiple sclerosis drug failed to reach the primary endpoint in a mid-stage study.
November 13, 2023
 · 
2 min read
 · 
Tyler Patchen
External view of AstraZeneca's production plant in Sweden
Drug Development
AstraZeneca’s Imfinzi, Chemo Combo Meets Endpoint in Phase III Liver Cancer
The company’s immunotherapy, in combination with chemotherapy Avastin, showed favorable progression-free survival in a late-stage hepatocellular carcinoma study.
November 10, 2023
 · 
2 min read
 · 
Tyler Patchen
Facade of the FDA's office in Maryland
FDA
Valneva Gets FDA’s First Chikungunya Vaccine Approval After Delay
Following a more than two-month delay to its PDUFA action date, Valneva’s chikungunya vaccine Ixchiq has won the regulatory race beating biotech Bavarian Nordic.
November 10, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: FTC sign above a doorway/iStock, Gromit7
Policy
FTC Challenges Over 100 Patents Listed on FDA’s Orange Book
The Federal Trade Commission is challenging over 100 pharmaceutical patents held by prominent drugmakers, including AbbVie, AstraZeneca and Boehringer Ingelheim, for their listings.
November 9, 2023
 · 
2 min read
 · 
Tyler Patchen
John Tlumacki/The Boston Globe via Getty Images
Business
Biogen Gets Q3 Beat, Reduces Full-Year Guidance on Costs of Reata Buy
While the biotech’s third-quarter revenue beat Wall Street expectations, its $7.3 billion acquisition of Reata Pharmaceuticals—which closed in September—negatively impacted 2023 per-share earnings.
November 9, 2023
 · 
2 min read
 · 
Tyler Patchen
Pictured: Eli Lilly's headquarters in Indianapolis
FDA
FDA Approves Eli Lilly’s Zepbound for Chronic Weight Management
Lilly’s Zepbound (tirzepatide) injection is the first and only approved treatment that activates two incretin hormone receptors, GIP and GLP-1, to treat obesity and excess weight.
November 8, 2023
 · 
2 min read
 · 
Tyler Patchen
Load More